Xynomic Pharma, a United States-based oncology research and development company, announced at the end of last month that it had entered into a partnership with the University of California San Francisco.
This partnership is for the purpose of conducting a randomized Phase 2/3 study of Pazopanib plus Abexinostat in the treatment of locally advanced or metastatic renal cell carcinoma.
Renal cell carcinoma is a type of kidney cancer that is extremely metastatic, i.e. fast-spreading. Thus, it is difficult to control and treat, especially in a situation of a recurrence. To learn more about this rare form of cancer, click here.
Abexinostat could potentially be used in these recurrence situations, where many other drugs are not nearly as effective, so the goal of this Phase 3 study is to leverage clinical data that was received from a recently completed Phase 1b study, in which durable tumor regressions were observed in 70% of patients.
This is groundbreaking new data that exhibited the first time that a drug can “prime” tumors and re-sensitize them to prior therapies.
Dr. Munster, an UCSF Professor claims that the new partnership will allow both parties
“to work closely with regulatory agencies to plan out the important Phase 2/3 trial, which could accelerate the development and potential approval of Abexinostat as the first epigenetic drug treating solid tumors.”
Hopefully, Abexinostat will soon be able to bring hope to all renal cell carcinoma patients, regardless of whether they are on their first round of treatment, or their last.
